Investigations concerning the influence of pharmacologic agents on transperitoneal water movement are predominantly undertaken in the hope that their results can help in a restoration of net ultrafiltration (UF) volume toward normal in cases with declining UF during long-term dialysis treatment. Net UF volume represents the difference between net transcapillary UF and lymphatic absorption.
The choice of a pharmacological agent for enhancing UF depends on the mechanisms responsible for net UF loss, which include: (a) early dissipation of the transperitoneal osmotic gradient; (b) decrease in the peritoneal surface area; (c) Iymphomonokine overproduction; (d) enhanced lymphatic absorption; (e) high residual volumes left in the peritoneal cavity; or (f) a combination of these factors. Leakage of dialysate to the abdominal wall sometimes occurring in peritoneally dialysed patients (1), according to a definition of net UF volume, cannot be regarded as a true UF loss.
RandersonD.H., FarellP.C.Mass transfer properties of the human peritoneum.ASAIO J.1980; 3: 140–146.
4.
MactierR.A., KhannaR., TwardowskiZ.Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis.J Clin Invest.1987; 80: 1311–1316.
5.
CantaluppiA., CastelnovoC., MoriggiM.Ultrafiltration failure in continuous ambulatory peritoneal dialysis. In: KhannaR., NolphK.D., ProwantB., TwardowskiZ.J., OreopoulosD.G., eds. Advances in continuous ambulatory peritoneal dialysis.University of Toronto Press: Perit. Dial. Bull. Inc; 1986: 12–15.
6.
RajaR.M., KramerM.S., BarberK.Solute transport and ultrafiltration during peritonitis in CAPD patients.ASAIO J.1984; 7: 8–11.
7.
SteinhauerH.B., SchollmeyerP.Prostaglandin-mediated loss of proteins in continuous ambulatory peritoneal dialysis.Kidney Int.1986; 29: 584–590.
8.
Heimburger0, WaniewskiJ., WerynskiA.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int.1990.
9.
NolphK.D., HopkinsC., RubinJ.Polymer induced ultrafiltration in dialysis: High osmotic pressure due to impermeant polymer sodium.Trans Am Soc Intern Organs.1978; 24: 162–168.
10.
MistryC.D., MallickN.P., GokalR.A sustained ultrafiltration characteristic of glucose polymer (GP2: MW 20000) during long dwell CAPD. (Abstr.) XXIIICongr Eur Dial Transplant Assoc.1986; 173.
11.
McGaryT.J., NolphK.D., KartinosN.J.Polyanions as osmotic agents in a simulated in vitro model of peritoneal dialysis.Trans Am Soc Artif Intern Organs.1981; 27: 314–318.
12.
MaherJ.F., HirszelP., LasrichM.Effects of gastrointestinal hormones on transport by peritoneal dialysis.Kidney Int.1979; 16: 130–136.
13.
HirszelP., LasrichM., MaherJ.F.Augmentation of peritoneal mass transport by dopamine. Comparison with norepinephrine and evaluation of pharmacologic mechanisms.J Lab Clin Med.1979; 94: 747–754.
14.
MaherJ.F., DiPaoloB., ShostakA.Pharmacology of peritoneal transport. In: KhannaR., NolphK.D., ProwantB., TwardowskiZ.J., OreopoulosD.G., eds. Advances in continuous ambulatory peritoneal dialysis.University of Toronto Press: Perit Dial Bull Inc; 1987: 3–6.
15.
DunhamC.B., HakL.J., HullJ.H.Enhancement of peritoneal dialysis clearance with docusate sodium.Kidney Int.1981; 20: 563–568.
16.
BreborowiczA., SombolosK., RodelaH.Mechanism of phosphatidylcholine action during peritoneal dialysis.Perit Dial Bull.1987; 7: 6–9.
17.
DiPaoloN., BuoncristianiV., GaggiottiE.Improvement of impaired ultrafiltration after phosphatidylcholine in patients on CAPD.Perit Dial Bull.1986; 6: 44–45.
18.
IndraprasitS., SooksriwongseC.Effect of chlorpromazine on peritoneal clearances.Nephron.1985; 40: 341343.
MaherJ.F., HirszelP., BennettR.R.Augmentation of peritoneal hydraulic permeability by amphotericin B: Locus of action.Perit Dial Bull.1984; 4: 229–231.
21.
MaherJ.F., HirszelP., ChakrabartiE.Increased peritoneal ultrafiltration due to amphotericin B augmented sodium transport. In: MaherJ.F., WinchesterJ.F., eds. Frontiers in peritoneal dialysis.New York: Field, Rich and Assoc, Inc; 1986: 106–109.
22.
LamperiS., CarozziS., NasiniM.G.Effect of intra-peritoneal verapamil therapy on ultrafiltration in CAPD patients with peritoneal hypopermeability. In: KhannaR., NolphK.D., ProwantB., TwardowskiZ.J., OreopoulosD.G., eds. Advances in continuous ambulatory peritoneal dialysis.University of Toronto Press: Perit Dial Bull Inc; 1984; 4: 15–20.
23.
LamperiS., CarozziS., NasiniM.G.Calcium antagonists improve ultrafiltration in patients on continuous ambulatory peritoneal dialysis.Trans Am Soc Artif Intern Organs.1987; 33: 657–663.
24.
LamperiS., Carozzi8, NasiniM.G.Lympho-monokine disorders and peritoneal fibroblast proliferation in CAPD.Trans Am Soc Artif Intern Organs.1986; 32: 3538.
25.
LamperiS., CarozziS.Lympho-monokine disorders and ultrafiltration loss in CAPD patients. In: KhannaR., NolphK.D., ProwantB., TwardowskiZ.J., OreopoulosD.G., eds. Advances in continuous ambulatory peritoneal dialysis.University of Toronto Press: Perit Dial Bull Inc; 1987: 7–12.
26.
LichtmanA.H., SegelG.B., LichtmanM.A.The role of calcium in lymphocyte proliferation: An interpretive review.Blood.1983; 61: 413–422.
27.
SullyS.P., SegelG.B., LichtmanM.A.Calcium exchange and ionized cytoplasmic calcium in resting and activated human monocytes.J Clin Invest.1984; 74: 589599.
28.
BurdielL.G., CastilloD., Martin-MaloA.Effect of verapamil and prostaglandin El on peritoneal membrane transport.Abstr. Eur Dial Transplant Assoc.1988; 95.
29.
SugaH., HondaH., SuzukiT.A low Ca++ level in effluent as a risk factor for the peritonitis in CAPD patients. Abstr.Perit Dial Int.1990; 10: 167.
30.
MactierR.A., KhannaR., TwardowskiZ.J.Failure of ultrafiltration in CAPD due to excessive lymphatic absorption.Am J Kid Dis.1987; 10: 461–466.
31.
MactierR.A., KhannaR., MooreH.Pharmacological reduction of lymphatic absorption from the peritoneal cavity increases net ultrafiltration and solute clearances in peritoneal dialysis.Nephron.1988; 50: 229–232.
32.
MactierR.A., KhannaR., TwardowskiZ.J.Influence of phosphatidylcholine on lymphatic absorption during peritoneal dialysis in the rat.Perit Dial Int.1988; 8: 179–186.
33.
KoelleG.B.Anticholinesterase agents. In: GoodmanA., GilsmanB., eds. The pharmacological basis of therapeutics (5th ed). New York: Macmillan, 1975; 445–466.
34.
SmebyL.C., WideröeT.E., JörstadS.Individual differences in water transport during continuous peritoneal dialysis.ASAIO J.1981; 4: 17–27.
35.
KredietR.T., StruijkD.G., BoeschotenE.W.The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis.Am J Kid Dis.1989; 13: 299–307.
36.
DobbieJ.W., HendersonI., WilsonL.S.New evidence on the pathogenesis of sclerosing encapsulating peritonitis (SEP) obtained from serial biopses. In: KhannaR., NolphK.D., ProwantB., TwardowskiZ.J., OreopoulosD.G., eds. Advances in continuous ambulatory peritoneal dialysis.University of Toronto Press: Perit Dial Bull Inc; 1987: 138–149.
37.
WebsterS.K., HuntenburgC.C., DinarelloC.A.Peritoneal solute transport is increased during inflammation and decreased during fibrosis in rats.Perit Dial Int.1990; 10: 186.
38.
SlingeneyerA., MionC., MouradG.Progressive sclerosis peritonitis: A late and severe complication of maintenance peritoneal dialysis.Trans Am Soc Artif Intern Organs.1983; 24: 633–640.
